# Treatment of RP and LCA by Primary RPE Transplantation

> **NCT03566147** · EARLY_PHASE1 · UNKNOWN · sponsor: **Eyecure Therapeutics Inc.** · enrollment: 30 (estimated)

## Conditions studied

- Leber Congenital Amaurosis, Retinitis Pigmentosa

## Interventions

- **BIOLOGICAL:** Human primary Retinal Pigment Epithelial (HuRPE) cells

## Key facts

- **NCT ID:** NCT03566147
- **Lead sponsor:** Eyecure Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-08-01
- **Primary completion:** 2019-12-31
- **Final completion:** 2020-03-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2018-08-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03566147

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03566147, "Treatment of RP and LCA by Primary RPE Transplantation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03566147. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*